Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer

被引：0
|
作者：
Chaudhary, U. B. [1 ]
Gudena, V. [1 ]
Milling, D. L. [1 ]
O'Brien, P. [1 ]
Montero, A. J. [1 ]
Brashears, J. [1 ]
Marshall, D. [1 ]
Hoffman, B. [1 ]
Garrett-Mayer, E. [1 ]
Esnaola, N. [1 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
    Esnaola, Nestor F.
    Chaudhary, Uzair B.
    O'Brien, Paul
    Garrett-Mayer, Elizabeth
    Camp, E. Ramsay
    Thomas, Melanie B.
    Cole, David J.
    Montero, Alberto J.
    Hoffman, Brenda J.
    Romagnuolo, Joseph
    Orwat, Kelly P.
    Marshall, David T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04): : 837 - 844
  • [2] Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
    Tran, Nguyen H.
    Sahai, Vaibhav
    Griffith, Kent A.
    Nathan, Hari
    Kaza, Ravi
    Cuneo, Kyle C.
    Shi, Jiaqi
    Kim, Edward
    Sonnenday, Christopher J.
    Cho, Clifford S.
    Lawrence, Theodore S.
    Zalupski, Mark M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (01): : 124 - 133
  • [3] Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer
    Kim, E. J.
    Ben-Josef, E.
    Griffith, K. A.
    Herman, J. M.
    Wolfgang, C. L.
    Bekaii-Saab, T. S.
    Bloomston, M.
    Dawson, L. A.
    Moore, M. J.
    Zalupski, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.
    Gupta, Niraj K.
    Singh, Kirpal
    Glass, Timothy
    Davis, Chad
    Lybik, Mark
    Leagre, Christopher
    Liebross, Robert H.
    Dugan, Thomas
    Edwards, Mark
    Givens, Stanley
    Compton, Julia
    Tigges, Thomas
    Flanders, Vincent
    Mathavan, Vinay
    Isch, Andrew
    Reeves, Dave
    Arevalo, Gabriel
    Rowe, Michael
    Kaderabek, Douglas
    Arregui, Maurice
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma
    Aybar, Pablo Emilio Serrano
    Herman, Joseph M.
    Zalupski, Mark
    Kim, Edward Jae-Hoon
    Ben-Josef, Edgar
    Bekaii-Saab, Tanios S.
    Wolfgang, Christopher Lee
    Laheru, Daniel A.
    Moore, Malcolm J.
    Dawson, Laura A.
    Ringash, Jolie
    Wei, Alice Chia-chi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer
    Joan Manel Gasent Blesa
    Javier Garde Noguera
    Juan Bautista Laforga Canales
    Vicent Giner Bosch
    Antonio Alberola
    Miguel Soler Tortosa
    Miguel Peris Godoy
    Jose Luis Sanchez
    Mariano Provencio Pulla
    Vicente Alberola Candel
    Journal of Gastrointestinal Cancer, 2012, 43 (4) : 553 - 561
  • [7] Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine/radiation in borderline resectable (BR) pancreatic cancer: A single-institution experience
    Gupta, Niraj K.
    Singh, Kirpal
    Aburajab, Murad
    Mathavan, Vinay
    Al-Satie, Mazen
    Glass, Timothy
    Leagre, Christopher A.
    Rowe, Michael
    Tigges, Thomas
    Liebross, Robert H.
    Davis, Chad
    Tandra, Sweta
    Tumati, Vas
    Tian, Jianmin
    Martinez, Brandon
    Dowell, Joshua
    Schmidt, Kristen Kay
    Flanders, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Four-Week Neoadjuvant Intensity-Modulated Radiation Therapy With Concurrent Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer Patients: A Validation Phase II Trial
    Arbea, Leire
    Martinez-Monge, Rafael
    Diaz-Gonzalez, Juan A.
    Moreno, Marta
    Rodriguez, Javier
    Luis Hernandez, Jose
    Javier Sola, Jesus
    Isaac Ramos, Luis
    Carlos Subtil, Jose
    Nunez, Jorge
    Chopitea, Ana
    Cambeiro, Mauricio
    Gaztanaga, Miren
    Garcia-Foncillas, Jesus
    Aristu, Javier
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (02): : 587 - 593
  • [9] A phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer
    Small, W.
    Talamonti, M.
    Normolle, D.
    Freedman, G.
    Berlin, J.
    Kinsella, T.
    Philip, P.
    Zalupski, M.
    Mulcahy, M.
    Meropol, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S172 - S173
  • [10] Quality of Life in a Multi-enter Phase II Trial of Neoadjuvant Full Dose Gemcitabine, Oxaliplatin and Radiation in Patients with Resectable or Borderline Resectable Pancreatic Adenocarcinoma
    Serrano, P. E.
    Herman, J. M.
    Laheru, D. A.
    Wolfgang, C.
    Zalupski, M. M.
    Kim, E. J.
    Bekaii-Saab, T. S.
    Moore, M. J.
    Dawson, L. A.
    Ringash, J. G.
    Wei, A. C.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S32 - S32
12345